Climb Bio, INC Form 4 insider transactions

Emily Pimblett, Chief Accounting Officer of Eliem Therapeutics, reports the conversion of restricted stock units and subsequent sale of shares to cover tax obligations.

Valerie Morisset, EVP, R&D and CSO of Eliem Therapeutics, exercised stock options on April 5, 2024, acquiring 17,847 shares of common stock.

Emily Pimblett, Chief Accounting Officer of Eliem Therapeutics, acquired 40,000 Restricted Stock Units (RSUs) on March 18, 2024, according to a Form 4 filing with the SEC.

Valerie Morisset, EVP, R&D and CSO of Eliem Therapeutics, exercised stock options at nominal prices, resulting in the acquisition of common stock.